HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $50
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $60 to $50.
HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $60 to $50.